ArticleCNS drugs2023

Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".

Maxwell Z Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.